Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation

被引:54
作者
Jirmanova, Ludmila [1 ]
Torchia, Maria Letizia Giardino [1 ]
Sarma, Nandakumara D. [1 ]
Mittelstadt, Paul R. [1 ]
Ashwell, Jonathan D. [1 ]
机构
[1] NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
GENE-TARGETED MICE; PROTEIN-KINASE; MAPK INHIBITOR; ARTHRITIS; P38-ALPHA; GAMMA; ALPHA; TH1; ENCEPHALOMYELITIS; PHOSPHORYLATION;
D O I
10.1182/blood-2011-01-333039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stimulation via the T-cell receptor (TCR) activates p38 alpha and p38 beta by phosphorylation of p38 Tyr-323 (p38(Y323)). Here we characterize knockin mice in which p38 alpha and/or beta Tyr-323 has been replaced with Phe. We find that p38 alpha accounts for two-thirds and p38 beta the remainder of TCR-induced p38 activation. T cells from double knockin mice (p38 alpha beta(Y323F)) had defects in TCR-mediated proliferation and Th1 and Th17 skewing, the former corresponding with an inability to sustain T-bet expression. Introduction of p38 alpha(Y323F) into Gadd45 alpha-deficient mice, in which the alternative p38 pathway is constitutively active, reversed T-cell hyperproliferation and autoimmunity. Furthermore, p38 alpha beta(Y323F) mice had delayed onset and reduced severity of the inflammatory autoimmune diseases collagen-induced arthritis and experimental autoimmune encephalomyelitis. Thus, T cell-specific alternative activation of p38 is an important pathway in T-cell proliferation, Th skewing, and inflammatory autoimmunity, and may be an attractive tissue-specific target for intervention in these processes. (Blood. 2011;118(12):3280-3289)
引用
收藏
页码:3280 / 3289
页数:10
相关论文
共 45 条
[1]   Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development [J].
Adams, RH ;
Porras, A ;
Alonso, G ;
Jones, M ;
Vintersten, K ;
Panelli, S ;
Valladares, A ;
Perez, L ;
Klein, R ;
Nebreda, AR .
MOLECULAR CELL, 2000, 6 (01) :109-116
[2]   Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy [J].
Alten, R. E. ;
Zerbini, C. ;
Jeka, S. ;
Irazoque, F. ;
Khatib, F. ;
Emery, P. ;
Bertasso, A. ;
Rabbia, M. ;
Caulfield, J. P. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (02) :364-367
[3]   The many paths to p38 mitogen-activated protein kinase activation in the immune system [J].
Ashwell, Jonathan D. .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (07) :532-540
[4]  
Atzeni F, 2009, CURR OPIN INVEST DR, V10, P1204
[5]  
Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
[6]   Generation and characterization of p38β (MAPK11) gene-targeted mice [J].
Beardmore, VA ;
Hinton, HJ ;
Eftychi, C ;
Apostolaki, M ;
Armaka, M ;
Darragh, J ;
McIlrath, J ;
Carr, JM ;
Armit, LJ ;
Clacher, C ;
Malone, L ;
Kollias, G ;
Arthur, JSC .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (23) :10454-10464
[7]   Selective requirement of p38α MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses [J].
Berenson, Lisa S. ;
Yang, Jianfei ;
Sleckman, Barry P. ;
Murphy, Theresa L. ;
Murphy, Kenneth M. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (08) :4616-4621
[8]  
Bingham CO, 2002, J RHEUMATOL, V29, P3
[9]   Spontaneous autoimmunity in 129 and C57BL/6 mice - Implications for autoimmunity described in gene-targeted mice [J].
Bygrave, AE ;
Rose, KL ;
Cortes-Hernandez, J ;
Warren, J ;
Rigby, RJ ;
Cook, HT ;
Walport, MJ ;
Vyse, TJ ;
Botto, M .
PLOS BIOLOGY, 2004, 2 (08) :1081-1090
[10]   Kinase inhibitors: a new approach to rheumatoid arthritis treatment [J].
Cohen, Stanley ;
Fleischmann, Roy .
CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (03) :330-335